SEARCH

SEARCH BY CITATION

References

  • 1
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: NAACCR Incidence-CiNA Analytic File, 1995-2008, for Expanded Races, Custom File With County, ACS Facts & Figures Projection Project, North American Association of Central Cancer Registries. Bethesda MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2011.
  • 2
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov. 2010 Sub (1973-2008 varying). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2011. Released April 2011 based on the November 2010 submission.
  • 3
    North American Association of Central Cancer Registries. NAACCR Guideline for Enhancing Hispanic-Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm (NHIA v2.2). Available at URL: http://www.naaccr.org/LinkClick.aspx?file ticket=i6MN9F8c1eU%3D&tabid=92. Acc essed November 1, 2011.
  • 4
    National Cancer Institute. SEER Summary Staging Manual-2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001.
  • 5
    Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. Available at: http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011. Accessed November 1, 2011.
  • 6
    World Health Organization. International Classification of Diseases for Oncology, 3rd edition. Geneva: World Health Organization; 2000.
  • 7
    Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008; 26: 612-619.
  • 8
    Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006; 24( suppl 3): S3/11-S3/25.
  • 9
    D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007; 356: 1944-1956.
  • 10
    Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19: 335-351.
  • 11
    Ederer F, Heise H. Instructions to IBM 650 Programmers in Processing Survival Computations. Methodological Note No. 10, End Results Evaluation Section. Bethesda, MD: National Cancer Institute; 1959.
  • 12
    Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007; 110: 1429-1435.
  • 13
    Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92: 709-720.
  • 14
    Brown LM, Check DP, Devesa SS. Oropharyngeal cancer incidence trends: diminishing racial disparities. Cancer Causes Control. 2011; 22: 753-763.
  • 15
    Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States [published online ahead of print October 3, 2011]. J Clin Oncol.
  • 16
    Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila). 2009; 2: 776-781.
  • 17
    Brawley OW. Oropharyngeal cancer, race, and the human papillomavirus. Cancer Prev Res (Phila). 2009; 2: 769-772.
  • 18
    Heck JE, Berthiller J, Vaccarella S, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010; 39: 166-181.
  • 19
    Schiffman M, Hildesheim A. Cervical cancer. In: Schottenfeld D, Fraumeni J, eds. Cancer Epidemiology and Prevention. New York: Oxford; 2006: 1044-1067.
  • 20
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 1915-1927.
  • 21
    Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374: 301-314.
  • 22
    Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011; 364: 401-411.
  • 23
    Blot W, McLaughlin J, Fraumeni J. Esophageal cancer. In: Schottenfeld D, Fraumeni J, eds. Cancer Epidemiology and Prevention. New York: Oxford; 2006: 697-706.
  • 24
    Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999; 130: 883-890.
  • 25
    Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340: 825-831.
  • 26
    Kim R, Weissfeld JL, Reynolds JC, Kuller LH. Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 1997; 6: 369-377.
  • 27
    Lagergren J. Controversies surrounding body mass, reflux, and risk of oesophageal adenocarcinoma. Lancet Oncol. 2006; 7: 347-349.
  • 28
    Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303: 235-241.
  • 29
    Li C, Ford ES, McGuire LC, Mokdad AH. Increasing trends in waist circumference and abdominal obesity among US adults. Obesity (Silver Spring). 2007; 15: 216-224.
  • 30
    Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008; 1: 329-338.
  • 31
    Wang KK, Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008; 103: 788-797.
    Direct Link:
  • 32
    Anderson KE, Mack TM, Silverman DT. Cancer of the pancreas. In: Schottenfeld D, Fraumeni J, eds. Cancer Epidemiology and Prevention. New York: Oxford; 2006: 721-762.
  • 33
    Berrington de Gonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer. 2003; 89: 519-523.
  • 34
    Silverman DT, Hoover RN, Brown LM, et al. Why do Black Americans have a higher risk of pancreatic cancer than White Americans? Epidemiology. 2003; 14: 45-54.
  • 35
    Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol. 2000; 74: 243-248.
  • 36
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144: 705-714.
  • 37
    London W, McGlynn K. Liver cancer. In: Schottenfeld D, Fraumeni J, eds. Cancer Epidemiology and Prevention. New York: Oxford; 2006: 763-786.
  • 38
    Varela M, Sala M, Llovet JM, Bruix J. Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev. 2003; 29: 99-104.
  • 39
    Ahmed F, Perz JF, Kwong S, Jamison PM, Friedman C, Bell BP. National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Prev Chronic Dis. 2008; 5: A74.
  • 40
    Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006; 28: 112-125.
  • 41
    Mast EE, Margolis HS, Fiore AE, et al; Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005; 54( RR-16): 1-31.
  • 42
    Mast EE, Weinbaum CM, Fiore AE, et al; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55( RR-16): 1-33; quiz CE1-CE4.
  • 43
    Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J Gastroenterol Hepatol. 2011; 26: 221-227.
  • 44
    Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
  • 45
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295: 2164-2167.
  • 46
    Davies L, Ouellette M, Hunter M, Welch HG. The increasing incidence of small thyroid cancers: where are the cases coming from? Laryngoscope. 2010; 120: 2446-2451.
  • 47
    Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid. 2011; 21: 125-134.
  • 48
    Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009; 115: 3801-3807.
  • 49
    Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009; 18: 784-791.
  • 50
    Ron E, Schneider A. Thyroid cancer. In: Schottenfeld D, Fraumeni J, eds. Cancer Epidemiology and Prevention. New York: Oxford; 2006: 975-994.
  • 51
    Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999; 281: 1628-1631.
  • 52
    Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol. 2002; 167: 57-60.
  • 53
    Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001; 93: 678-683.
  • 54
    Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol. 2008; 128: 2905-2908.
  • 55
    Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002; 94: 2766-2792.
  • 56
    National Cancer Institute. Voices of a Broken System: Real People, Real Problems. President's Cancer Panel: Report of the Chairman 2000-2001. Bethesda, MD: National Institutes of Health; 2001.
  • 57
    American Society of Clinical Oncology. Forecasting the Supply of and Demand for Oncologists: A Report to the American Society of Clinical Oncology (ASCO) from the AAMC Center for Workforce Studies. Available at URL: http://www.asco.org/ASCO/Downloads/Cancer%20 Research/Oncology%20Workforce%20 Report%20FINAL.pdf. Accessed November 1, 2011.
  • 58
    Wu XC, Yu Q, Andrews PA, et al. Comparisons of directly coded SEER Summary Stage 2000 and Collaborative Staging Derived SEER Summary Stage 2000. J Registry Manag. 2010; 37: 137-140.